Media headlines about Cardiome Pharma (NASDAQ:CRME) (TSE:COM) have been trending somewhat positive on Thursday, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cardiome Pharma earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.2796319138232 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Cardiome Pharma (NASDAQ:CRME) traded up $0.02 on Thursday, hitting $1.59. 63,291 shares of the stock traded hands, compared to its average volume of 58,311. The company has a current ratio of 5.52, a quick ratio of 4.71 and a debt-to-equity ratio of 1.67. Cardiome Pharma has a fifty-two week low of $1.29 and a fifty-two week high of $4.84. The company has a market cap of $54.30, a price-to-earnings ratio of -1.92 and a beta of 0.83.
Cardiome Pharma (NASDAQ:CRME) (TSE:COM) last posted its earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.04). The firm had revenue of $6.02 million during the quarter, compared to the consensus estimate of $7.42 million. Cardiome Pharma had a negative return on equity of 94.68% and a negative net margin of 112.91%. The firm’s revenue for the quarter was up 14.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.19) EPS. sell-side analysts predict that Cardiome Pharma will post -0.84 EPS for the current fiscal year.
A number of analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Cardiome Pharma from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th. Mackie raised shares of Cardiome Pharma to a “buy” rating in a research report on Friday, December 15th. Canaccord Genuity set a $5.00 target price on shares of Cardiome Pharma and gave the stock a “buy” rating in a research report on Wednesday, November 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $9.50 target price on shares of Cardiome Pharma in a research report on Wednesday, November 22nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $5.50.
ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.dispatchtribunal.com/2018/01/12/cardiome-pharma-crme-getting-somewhat-positive-media-coverage-analysis-finds.html.
Cardiome Pharma Company Profile
Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome.
Receive News & Ratings for Cardiome Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma and related companies with MarketBeat.com's FREE daily email newsletter.